Quantcast
Last updated on April 17, 2014 at 11:16 EDT

Latest Carboplatin Stories

2009-05-12 07:00:00

INDIANAPOLIS, May 12 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) will unveil data from more than 50 studies at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla. from May 29 to June 2, 2009, with the majority of the presentations continuing to support Lilly's leadership in thoracic cancer research. The company will present the latest research findings on ALIMTA(R) (pemetrexed for injection), as well as GEMZAR(R) (gemcitabine HCl for...

2009-04-27 07:00:00

- Updated Data from Initial Cohort Shows Nine of 14 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response - - Patient Dosing Underway in Expansion Stage of Trial with Target of Enrolling 46 Patients Overall - TUSTIN, Calif., April 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that updated preliminary data from its Phase II trial evaluating bavituximab in combination with...

2009-04-20 06:45:00

- Updated Data from Initial Cohort Shows 11 of 17 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response - - Patient Dosing Initiated in Expansion Stage of Trial with Target of Enrolling 49 Patients Overall - TUSTIN, Calif., April 20 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that updated preliminary data from the initial cohort of 21 patients in its Phase II trial evaluating...

2009-04-19 09:37:30

 The addition of a chemotherapeutic drug for leukemia to a standard regimen of two other chemotherapy drugs appears to enhance the response of certain ovarian cancers to treatment, according to a pre-clinical study led by researchers in the Duke Comprehensive Cancer Center."We know that a pathway called SRC is involved in cell proliferation in certain types of cancers, including some ovarian cancers," said Deanna Teoh, M.D., a fellow in gynecologic oncology at Duke and lead investigator...

2009-03-23 07:00:00

EXTON, Pa., March 23 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that the U.S. Food and Drug Administration (FDA) has agreed to and approved the design of a single, pivotal, Phase III clinical trial evaluating farletuzumab (also known as MORAb-003) in platinum-sensitive ovarian cancer patients experiencing their first relapse. The agreement was made under the Special Protocol Assessment (SPA) procedure. "We are pleased that the FDA...

2009-03-20 10:59:00

CALGARY, March 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim clinical results from its Phase I/II U.K. trial of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers were presented at the Fifth International Meeting on Replicating Oncolytic Virus Therapeutics. The meeting is being held in Banff, Alberta from March 18th to 22nd, 2009. The principal investigator for the trial is Dr. Kevin Harrington of The...

2009-03-12 12:45:00

CALGARY, March 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours. The Principal Investigator is Dr. Miguel Villalona-Calero, Professor, Division of Hematology/Oncology and Department of...

2009-03-04 16:57:00

CALGARY, March 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today reported its financial results for the year ended December 31, 2008. "In 2008, we selected our first pivotal program for REOLYSIN(R)," said Dr. Brad Thompson, President and CEO of Oncolytics. "The selection of head and neck cancers was supported by interim results reported in our US and UK clinical studies, and the successful development of a manufacturing process...

2009-02-04 05:00:00

BOTHELL, WA, and VANCOUVER, Feb. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the two-year survival rate from a Phase 1/2 clinical trial of OGX-011 in combination with first-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). At two years, 30% of patients who had received OGX-011 with first-line chemotherapy were alive. OncoGenex has previously reported a mature median survival of 14.1 months and a one-year survival...

2009-01-08 08:38:00

MONTREAL, Jan. 8 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2 study of AEG35156, their targeted antisense therapeutic in mid-stage development for multiple oncology indications. The study, entitled "A Phase 2, Multicenter, Open-Label, Randomized Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given In Combination With Carboplatin/Paclitaxel or the Combination of Carboplatin/Paclitaxel Alone In Patients...